EMEA-001696-PIP01-14-M02 - paediatric investigation plan

Omecamtiv mecarbil

Key facts

• Active Substance:
  Omecamtiv mecarbil
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/0260/2022
• PIP number:
  EMEA-001696-PIP01-14-M02
• Pharmaceutical form(s):
  Modified-release tablet
• Condition(s) / indication(s):
  Treatment of heart failure
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Cytokinetics, Inc.

  Tel.: [phone]; E-mail: [e-mail]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  22/07/2022

Decision

P/0260/2022 : EMA decision of 15 July 2022 on the acceptance of a modification of an agreed paediatric investigation plan for omecamtiv mecarbil (EMEA-001696-PIP01-14-M02)

Reference Number: EMA/624973/2022